MDL Track
MDL 3140
N.D. Fla.
Depo-Provera medroxyprogesterone acetate products liability
3,099 pending
Pharmaceutical · claims focused on contraceptive injection side effects and alleged long-term harms
Defendant
Pfizer Inc.
MDL / Track
MDL 3140
N.D. Fla.
Judge
Judge M. Casey Rodgers
Plaintiffs
~3,356 pending (3,099 per JPML March 2, 2026 report, plus 257 new filings tracked)
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
Pfizer reached a global settlement agreement in principle on June 15, 2026, to resolve thousands of meningioma claims in MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida, with final terms still being negotiated. The litigation grew from 78 cases in March 2025 to over 5,500 by June 2026, with the first bellwether trial — Blonski v. Pfizer Inc. — scheduled for December 7, 2026. Plaintiffs allege Pfizer failed for decades to warn that Depo-Provera's medroxyprogesterone acetate increases meningioma risk, with the first U.S. label warning added only in December 2025 at Pfizer's request.
Causation Theory
Meningiomas express progesterone receptors and can grow in response to progestin exposure. A March 2024 BMJ study of 108,366 French women found 5.55 times the odds of meningioma in injectable medroxyprogesterone acetate users versus non-users, with risk concentrated in long-term use. A November 2025 TriNetX study confirmed a 2.43x relative risk in women using the injection for four or more years who were older than 31 at first use. The FDA approved a meningioma warning in December 2025 stating that cases have been reported following repeated administration, primarily with long-term use.
Case Management Orders
Litigation status
Judge M. Casey Rodgers confirmed a global settlement in principle on June 15, 2026, with parties signing a formal Master Settlement Agreement on July 21, 2026. The court estimates ~80% of MDL plaintiffs will be eligible; Daubert hearing reset to July 27, 2026 for non-settling claims.
MDL Track
MDL 3140
N.D. Fla.
Depo-Provera medroxyprogesterone acetate products liability
3,099 pending
State Court Activity
Hundreds pending: ~332 in Delaware Superior Court (Judge Kathleen Vavala), 72 in New York, 21 in California; Delaware held independent Daubert hearing June 26, 2026
MDL 3140 Leadership
Plaintiff Leadership
Lead Counsel
Co-Lead Counsel
Liaison Counsel
Defense Leadership
Liaison Counsel
Geographic exposure
Estimated 5,549+ cases in federal MDL; 500+ additional cases in Delaware, New York, California, Pennsylvania, Illinois, New Mexico state courts. Thousands of unfiled claims held pending causation determinations. Primary exposure: women with long-term Depo-Provera use developing intracranial meningiomas. U.S. label lacked meningioma warning until December 2025—decades after EU/Canadian regulatory warnings.
MDL No. 3140, Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, before Judge M. Casey Rodgers. As of May 2026, 5,549 federal cases pending. Tentative global settlement reached June 2026 covering MDL-eligible plaintiffs; excludes state court cases. Daubert hearing on general causation scheduled June 24-26, 2026 postponed.
340 cases pending in Delaware Superior Court as of May 2026, overseen by Judge Kathleen Vavala. Excluded from MDL settlement. State court proceedings continue with separate scheduling.
119 cases pending in state courts as of May 2026. Excluded from MDL settlement. Additional filings ongoing.
91 cases pending in state courts as of May 2026. Eleven cases awaiting coordination. Central District of California: Edgerton, Fazio, White. Northern District of California: Valera-Arceo.
Philadelphia Court of Common Pleas emerging as secondary venue. Three cases including mass complaint with 100 claimants. Viatris Inc. headquartered in Pennsylvania permits nationwide plaintiff filings.
Individual actions pending. Daniels matter transferred to MDL No. 3140.
Individual actions pending in state court.
Neolpharma Inc.-PBG Puerto Rico LLC facility, Caguas (99 Jardines Street). Former Pfizer manufacturing site. EPA RCRA corrective action for groundwater contamination: 1,2-DCA, 1,2-DCP, PCE, chloroform, benzene detected. No current human health exposure pathway per 2010 assessment. Groundwater monitoring ongoing through November 2024.
Key defendants
Pfizer Inc.
Role: Manufacturer, NDA Holder
Primary target in MDL 3:25-md-03140 before Judge M. Casey Rodgers in N.D. Fla. Pushing preemption defense; Daubert hearings in spring 2025 largely preserved plaintiffs' expert testimony. Core exposure on failure-to-warn claims for meningioma risk.
Viatris Inc.
Role: Manufacturer
Named in MDL and individual complaints including 3:24-cv-06875-LB (N.D. Cal.). Co-defendant with Pfizer; litigation posture appears coordinated with Pfizer defense.
Prasco Laboratories
Role: Authorized Generic Manufacturer
Named defendant in 3:24-cv-06875-LB and MDL. Holds 'sizeable' U.S. market share per complaint. Smaller exposure profile than Pfizer/Viatris.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Pfizer Inc. | Manufacturer, NDA Holder | Primary target in MDL 3:25-md-03140 before Judge M. Casey Rodgers in N.D. Fla. Pushing preemption defense; Daubert hearings in spring 2025 largely preserved plaintiffs' expert testimony. Core exposure on failure-to-warn claims for meningioma risk. |
| Viatris Inc. | Manufacturer | Named in MDL and individual complaints including 3:24-cv-06875-LB (N.D. Cal.). Co-defendant with Pfizer; litigation posture appears coordinated with Pfizer defense. |
| Prasco Laboratories | Authorized Generic Manufacturer | Named defendant in 3:24-cv-06875-LB and MDL. Holds 'sizeable' U.S. market share per complaint. Smaller exposure profile than Pfizer/Viatris. |
Timeline
BMJ Publishes Landmark Meningioma Study
French case-control study published in The BMJ finds 5.55-fold increased risk of intracranial meningioma with prolonged medroxyprogesterone acetate use.
First Depo-Provera Lawsuits Filed
Initial meningioma lawsuits filed against Pfizer, alleging failure to warn of brain tumor risk. European and Canadian labels already carried meningioma warnings; U.S. label did not.
MDL-3140 Established in N.D. Florida
Judicial Panel on Multidistrict Litigation centralizes federal Depo-Provera cases as MDL No. 3140, In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, before Judge M. Casey Rodgers in Pensacola.
JAMA Neurology Confirms Meningioma Risk
Cleveland Clinic study published in JAMA Neurology (n=10.4M) finds 2.43-fold increased meningioma risk with prolonged Depo-Provera use.
FDA Approves U.S. Meningioma Warning
FDA approves new meningioma warning on Depo-Provera U.S. label, first such disclosure in over 30 years since 1992 contraceptive approval. Warning states: 'Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.'
Judge Rodgers Orders Bellwether Schedule
Judge M. Casey Rodgers enters case management order establishing five pilot cases for bellwether trials, with first trial (Toney v. Pfizer) set for December 7, 2026, and four additional trials for January 2027.
Global Settlement in Principle Reached
Judge Rodgers enters order confirming global agreement in principle between plaintiffs' lead counsel and Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC. First bellwether trial vacated; Daubert hearing reset from June 24-26 to July 27, 2026. JPML report shows 5,508 pending cases (5,590 total filed).
Daubert Hearing on General Causation
Rescheduled Rule 702 hearing on plaintiffs' general causation experts to proceed in Pensacola for cases outside settlement agreement.
Statute of limitations
No MDL established for Depo-Provera as of March 2026. First lawsuit filed October 2024. Critical accrual issue: March 2024 BMJ study established Depo-Provera-meningioma link, triggering discovery-rule arguments nationwide. Pfizer faces failure-to-warn claims; no federal preemption defense yet tested. Screen for diagnosis date AND date of discovery of causal link. States with 1-year SOL (KY, LA, TN) present imminent bar risk for pre-2024 diagnoses.
⚠Louisiana
1 year from discovery
Rule: La. Civ. Code art. 3492; discovery rule applies per March 2024 BMJ study establishing causal link
Discovery: Clock starts when plaintiff knew or should have known of Depo-Provera-meningioma connection, not diagnosis date alone
Shortest SOL nationwide; pre-2024 diagnoses at acute bar risk without discovery tolling
⚠Kentucky
1 year from discovery
Rule: Ky. Rev. Stat. § 413.140(1)(a); discovery rule recognized for latent injuries
Discovery: Accrues upon discovery of injury and its cause; March 2024 study triggers new knowledge
One-year window creates immediate intake urgency for any 2024 diagnoses
⚠Tennessee
1 year from discovery
Rule: Tenn. Code Ann. § 28-3-104; discovery rule applies for latent diseases
Discovery: Accrues when injury is discovered or should have been discovered with reasonable diligence
No product liability repose statute; discovery rule critical for pre-2024 Depo use
California
2 years from discovery
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule codified at § 338
Discovery: Accrues upon discovery of injury and its negligent cause; March 2024 study resets clock for many
Large plaintiff pool; courts liberal on discovery rule for pharmaceutical latency
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies
Discovery: Accrues when plaintiff knows or should know of injury and its cause in fact
No statutory repose for pharmaceutical claims; 15-year repose for products liability generally inapplicable to failure-to-warn
Florida
4 years from discovery
Rule: Fla. Stat. § 95.11(3)(a); discovery rule applies via case law
Discovery: Accrues upon discovery of injury and causal connection; longer window than most states
No product liability repose; favorable for latent pharmaceutical injuries
Missouri
5 years from discovery
Rule: Mo. Rev. Stat. § 516.120; discovery rule applies for latent injuries
Discovery: Accrues upon discovery of injury and its cause; among longest SOLs nationally
Extended window reduces immediate bar risk; screen for out-of-state defendants for venue
New York
3 years from discovery
Rule: N.Y. C.P.L.R. § 214(5); discovery rule applies for foreign-object and latent disease cases
Discovery: Accrues upon discovery of injury and its cause; continuous treatment doctrine may toll
No statutory repose; favorable discovery jurisprudence for pharmaceutical claims
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| ⚠Louisiana | 1 year from discovery | La. Civ. Code art. 3492; discovery rule applies per March 2024 BMJ study establishing causal link | Clock starts when plaintiff knew or should have known of Depo-Provera-meningioma connection, not diagnosis date alone | Shortest SOL nationwide; pre-2024 diagnoses at acute bar risk without discovery tolling |
| ⚠Kentucky | 1 year from discovery | Ky. Rev. Stat. § 413.140(1)(a); discovery rule recognized for latent injuries | Accrues upon discovery of injury and its cause; March 2024 study triggers new knowledge | One-year window creates immediate intake urgency for any 2024 diagnoses |
| ⚠Tennessee | 1 year from discovery | Tenn. Code Ann. § 28-3-104; discovery rule applies for latent diseases | Accrues when injury is discovered or should have been discovered with reasonable diligence | No product liability repose statute; discovery rule critical for pre-2024 Depo use |
| California | 2 years from discovery | Cal. Code Civ. Proc. § 335.1; discovery rule codified at § 338 | Accrues upon discovery of injury and its negligent cause; March 2024 study resets clock for many | Large plaintiff pool; courts liberal on discovery rule for pharmaceutical latency |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies | Accrues when plaintiff knows or should know of injury and its cause in fact | No statutory repose for pharmaceutical claims; 15-year repose for products liability generally inapplicable to failure-to-warn |
| Florida | 4 years from discovery | Fla. Stat. § 95.11(3)(a); discovery rule applies via case law | Accrues upon discovery of injury and causal connection; longer window than most states | No product liability repose; favorable for latent pharmaceutical injuries |
| Missouri | 5 years from discovery | Mo. Rev. Stat. § 516.120; discovery rule applies for latent injuries | Accrues upon discovery of injury and its cause; among longest SOLs nationally | Extended window reduces immediate bar risk; screen for out-of-state defendants for venue |
| New York | 3 years from discovery | N.Y. C.P.L.R. § 214(5); discovery rule applies for foreign-object and latent disease cases | Accrues upon discovery of injury and its cause; continuous treatment doctrine may toll | No statutory repose; favorable discovery jurisprudence for pharmaceutical claims |
Live intelligence
AI litigation brief
Depo-Provera remains early-stage / pre-daubert with 297 current signals in the accepted feed.
Overview
Judge M. Casey Rodgers confirmed a global settlement in principle on June 15, 2026, with parties signing a formal Master Settlement Agreement on July 21, 2026. The court estimates ~80% of MDL plaintiffs will be eligible; Daubert hearing reset to July 27, 2026 for non-settling claims.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3140, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3140 should stay on the lead docket watch because it is the primary consolidation vehicle for Depo-Provera.
Generated Aug 12, 2026, 2:00 AM UTC
297 events detected
Google News (32)
Judge Says Depo-Provera MDL Settlement Terms Will Be Explained At Town Hall Meeting - Mealey's
What the Depo-Provera Settlement Means for Meningioma Brain Tumor Lawsuits - JD Supra
Vigna Law Group: Bellwether Early Use of Depo-Provera in Focus, 1992-2002 - EIN Presswire
Depo-Provera MDL Judge Grants Motion For New Pilot Cases After Some Cases Settle - Mealey's
Depo-Provera MDL Gets New Lead Plaintiffs After Settlement - law360.com
Depo Provera Lawsuit Settlement (July 2026) - LawFold.com
Latency: Depo-Provera and Meningioma in Focus; California Bellwethers on the Horizon - The National Law Review
Birth Control: Depo-Provera, IUDs Tied to Higher Brain Tumor Risk - Healthline
It’s not just Depo-Provera — study links 5 more birth control drugs to brain tumor risk - New York Post
‘I have an inoperable brain tumour after having the contraceptive jab’ - The Independent
Common Hormonal Contraceptive Linked to Risk of Rare Brain Tumor - ScienceAlert
Pfizer's Depo-Provera Settlement: What Women With Meningioma Need to Know About the June 2026 Agreement - JD Supra
Study Links Several Progestogen Contraceptives to Rare Meningioma Risk, Reinforcing Individualized Patient Counseling - Pharmacy Times – Pharmacy Practice News and Expert Insights
New Evidence Links Progestogen Contraceptives to Brain Tumor Risk - MedPage Today
'I got three brain tumours after taking contraceptive injection' - BBC
Her Case Matters Explains the Upcoming June 24 Depo-Provera(R) Hearing for Women Who Trusted the Birth Control - The Daily Reflector
Pfizer Reaches Tentative Settlement in Depo-Provera Cases, Bellwether Trial Vacated - Law.com
Edinburgh inquiry demand from women with brain tumours after contraceptive jabs - Yahoo News UK
Pfizer Agrees To Deal To End Depo-Provera MDL - Law360
Depo-Provera Brain Tumor MDL Adds 1,700 Cases in 1 Month - The Legal Examiner
Depo-Provera Brain Tumor MDL Adds 1,700 Cases in One Month - The Legal Examiner
Pfizer Brought into a Depo-Provera Meningioma Claim in Clark County, WA - EIN News
11th Circ. Won't Stop Joint Hearing In Depo-Provera MDL - Law360
Women suing Pfizer over 'brain tumour link to contraceptive injection' - Sky News
Depo Provera Lawsuit Settlements: 2026 Payout Guide - LawFold.com
Nine New Mexico women allege brain tumors from injectable birth control in lawsuit - Santa Fe New Mexican
Nine New Mexico women allege brain tumors from injectable birth control in lawsuit | Local News - Santa Fe New Mexican
Depo-Provera Litigation Explained: What Women Should Know About Emerging Brain Tumor Claims - KHTS Radio
Who qualifies for the birth control shot lawsuit and how to check - INQUIRER.net USA
Birth Injury Justice Center Responds to Rapidly Expanding Depo-Provera Brain Tumor Litigation - reflector.com
Pfizer faces 2026 trial as brain tumour claims multiply - ICLG
Legal-Bay Pre Settlement Funding Provides Financial Support for Plaintiffs in Depo-Provera Litigation - PR Newswire
Journal of neurosurgery. Case lessons • Arnautović KI • PMID 42508056 • Journal Article.
European journal of radiology • Zhang J • PMID 42476061 • Journal Article.
Medicine • Koçer Ş • PMID 42470019 • Journal Article.
Journal of clinical medicine • Muquit S • PMID 42513474 • Journal Article.
JAMA network open • Wessel Skovlund C • PMID 42390859 • Journal Article.
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket filed in JPML: Plaintiffs are suing Defendants Pfizer Inc., Viatris Inc., Greenstone LLC, Prasco, LLC, Pharmacia & Upjohn Co. LLC, and Pharmacia LLC because of injuries allegedly caused by the drug Depo-Provera. Plaintiff claims that the use of Depo-Provera led to the development of an intracranial meningioma, a t
Stipulated Order — Discontinuance of Claims Against Greenstone Defendants
This stipulated pretrial case management order sets forth processes and deadlines for voluntarily dismissing without prejudice claims against Greenstone LLC and Viatris Inc. in the coordinated Depo-Provera litigation.
Pretrial Order No. 1 — Initial MDL Procedures
Establishes initial case management procedures for MDL No. 3140, including appointment of liaison counsel, scheduling of initial conference, and setting deadlines for pleadings and discovery.
Case Management Order No. 14 — Settlement Program Implementation
flnd_html
The Court issues Case Management Order No. 14 to address the ongoing litigation following the parties' entry into a settlement program, noting the registration deadline and procedures for ineligible claimants.
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket entry from FLND: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number AFLNDC-10000790.), filed by KATHERINE HUIE. (Attachments: # 1 Civil Cover Sheet) (DAVIS, STEVEN) (Entered: 08/10/2026)
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket entry from FLND: COMPLAINT against PFIZER INC, PHARMACIA & UPJOHN COMPANY LLC, PHARMACIA LLC ( Filing fee $ 405 receipt number AFLNDC-9999639.), filed by KRISTINA RIETVELD. (Attachments: # 1 Civil Cover Sheet) (FINKEN, TRACY) (Main Document 1 replaced on 8/10/2026) (djb). (Entered: 08/10/2026)
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket entry from FLND: COMPLAINT against PFIZER INC, PHARMACIA & UPJOHN COMPANY LLC, PHARMACIA LLC ( Filing fee $ 405 receipt number AFLNDC-9999487.), filed by NAN HAGAN MORNINGSTAR, JOHN MORNINGSTAR. (Attachments: # 1 Civil Cover Sheet) (FINKEN, TRACY) (Entered: 08/10/2026)
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket entry from FLND: COMPLAINT against PFIZER INC, PHARMACIA & UPJOHN COMPANY LLC, PHARMACIA LLC ( Filing fee $ 405 receipt number AFLNDC-9997705.), filed by NICOLE RICE. (Attachments: # 1 Civil Cover Sheet) (FINKEN, TRACY) (Entered: 08/07/2026)
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket entry from FLND: COMPLAINT against PFIZER INC, PHARMACIA & UPJOHN COMPANY LLC, PHARMACIA LLC ( Filing fee $ 405 receipt number AFLNDC-9996639.), filed by HEATHER CUSIC. (Attachments: # 1 Civil Cover Sheet) (FINKEN, TRACY) (Entered: 08/07/2026)
Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation
PACER docket entry from FLND: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number AFLNDC-9995589.), filed by NATALIE WORTHINGTON. (Attachments: # 1 Civil Cover Sheet) (DWORAK, PAUL) (Entered: 08/06/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
92Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Aug 12, 2026, 2:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
297
events detected
AI Brief
Depo-Provera remains early-stage / pre-daubert with 297 current signals in the accepted feed.
Overview
Judge M. Casey Rodgers confirmed a global settlement in principle on June 15, 2026, with parties signing a formal Master Settlement Agreement on July 21, 2026. The court estimates ~80% of MDL plaintiffs will be eligible; Daubert hearing reset to July 27, 2026 for non-settling claims.
Key developments
PACER court filing on Dec 31: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation. ‖ Mealey's news on Aug 5: Judge Says Depo-Provera MDL Settlement Terms Will Be Explained At Town Hall Meeting - Mealey's. ‖ FAERS FDA alert on Jul 9: FAERS Filing 26945233: Meningioma. ‖ PubMed research on Jul 27: Purely cystic meningioma: extremely rare clinical and radiographic mimic of intra-axial glioblastoma multiforme with systematic review of the literature. Illustrative case..
Generated Aug 12, 2026, 2:00 AM UTC
Tracked MDLs
MDL 3140
N.D. Fla.
Depo-Provera medroxyprogesterone acetate products liability